Clinigen Group Company
Clinigen Group
The Clinigen Group is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.
To achieve our aim, we have built a group of complementary businesses which operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. In April 2015, Clinigen acquired Idis, the market leader in the global supply of unlicensed medicines and the Group now operates as four synergistic businesses: Clinigen Specialty Pharmaceuticals, Clinigen Clinical Trial Services, Idis Managed Access (this now includes the previously branded Clinigen GAP business) and Idis General Access.
Headquartered in the UK and with offices in the US and Japan, Clinigen has the ability and capability to acquire, license and revitalise niche, hospital-only critical care medicine and to source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.
Clinigen has seen six-fold revenue growth over the past four years and our work has been recognised in being recently named the winner of the Business of the Year Award with Turnover of €26-150m at the 2014/15 European Business Awards.
